|
...a key milestone in the advancement of UCB's epilepsy franchise and re-enforces our commitment to the development of new treatment options for people with epilepsy," said Iris Loew-Friedrich, MD, PhD, Global Head of Development, UCB. "Today up to 30% of patients can be resistant to current antiepileptic medications and UCB's research and development programmes aim to support this significant unmet medical need."
Nearly 1300 epilepsy...
NOTE: All illustrations and photos
have been removed from this article.
More articles from Worldwide Biotech
BIOLINERX REPORTS POSITIVE RESULTS FROM BL-1020 TRIAL.(Clinical report..., December 01, 2007
SNT-MC17 PHASE IIA FOR MUSCULAR DYSTROPHY ENCOURAGING.(Clinical report..., December 01, 2007
SURVIVAL ANALYSIS FROM SATRAPLATIN TRIAL DISAPPOINTING., December 01, 2007
Looking for additional articles?
Search our database of over 3 million articles.
Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication
name or publication date.
About Goliath
Whether you're looking for sales prospects, competitive information, company
analysis or best practices in managing your organization,
Goliath can help you meet your business needs.
Our extensive business information databases empower business
professionals with both the breadth and depth of credible,
authoritative information they need to support their business
goals. Whether it be strategic planning, sales prospecting,
company research or defining management best practices -
Goliath is your leading source for accurate information.
|
